Day Three - ET (Eastern Time, GMT-05:00)
- Katelyn Reichheld - Conference Producer, Informa Connect
- Lilian Buch - Senior Director, Market Access, Glaukos
Identifying patient population size more accurately
Understanding the payer mix beyond claims data
Aligning sales targeting and tailored marketing messaging to IDN HCPs
Opening alternative distribution methods and partnerships with vendors
- Jerry Taglianetti - Vice President, Market Access, Loopback Analytics
Join John as he completely oversteps his authority and recommends changes to 340B, MDRP, and IRA policy that HHS should make in 2025. Equal time will neither be given nor offered to opposing views.
- John Shakow - Partner, King & Spalding LLP
- IRA Final Rule timeline and implementation status
- 340B examined and alternative rebate model
- Chevron insights
- Post election modeling
- Medicaid final rule implementation
- Tom Evegan - Principal, National Consulting Leader, Life Sciences, RSM US LLP
- Alice Valder Curran - Partner, Global Regulatory, Hogan Lovells
- Trevor Wear - Partner, Sidley Austin LLP
- Stephanie Trunk - Partner, ArentFox Schiff LLP
- Margaux Hall - Partner, Ropes & Gray LLP
- Hear from the customer: What factors health plans consider when evaluating contract opportunities
- The biggest hurdles health plans face with current contracting models
- How health plans are working with partners to develop new contracting strategies and new structures being brought to market
- Matt Hinchey - Head of Pharma Solutions, Evio Pharmacy Solutions
- Greg Gambescia - Director of Specialty Pharmacy, Independence Blue Cross
- AI/ML implementation for contract management -Predictive analytics for pricing optimization
- Advanced reporting and dashboard development
- System integration automation
- Performance optimization through data analysis
- David Salazar - Associate Director of Contracts and Pricing, UCB Inc
- David W. Gould - Chief Customer Officer, Encompaas
Manufacturers increasingly seek comprehensive assessments of their GP Compliance Programs. Rather than traditional evaluations, we've developed a collaborative "GP Enhancement Project" approach. This iterative process involves deep-diving into documentation, methodology, and calculations while working alongside manufacturers to implement improvements in real-time. Learn how this partnership model helps companies build sustainable GP Compliance Programs with confidence.
- Chris Cobourn - Managing Director, Government Pricing Practice Lead, Helio
- John Shakow - Partner, King & Spalding LLP
- Cindy Cerneka - Managing Director, Government Pricing, Helio
Master evolving competitive dynamics between originators, biosimilars, and generics - examining real-world pricing strategies, PBM pressures, and channel optimization approaches across product types
Balance profitability amid complex government program requirements, wholesaler fee structures, and membership validation challenges unique to biosimilar and generic business models
Optimize operational execution across distribution channels while managing intricate chargeback processes and contract pharmacy relationships in an increasingly competitive landscape
Analyze how IRA implementation, Medicare Part D redesign, and emerging PBM policies are reshaping market access opportunities and contracting approaches for non-brand manufacturers
Future-proof your strategy by understanding shifting payor dynamics, regulatory requirements, and market entrant impacts on biosimilar and generic positioning
- Rodney Emerson - Vice President, Pricing & Contracts, Sandoz
Join fellow senior leaders for an elevated lunch experience where you'll engage in facilitator-guided conversations on mission-critical topics impacting pharmaceutical manufacturers in 2025, including IRA implementation impacts, evolving PBM dynamics, state-level policy shifts, and strategic GTN management. This closed-door session provides a confidential environment for authentic dialogue and solution sharing.
Invitation-only gathering limited to 35 participants. Email katelyn.reichheld@informa.com for more details.
- Rosalind Davis - Head of Government Pricing and Market Access Operations, CSL Vifor
- What ancillary evidence is beneficial to establish favorable CGT coverage policy beyond the clinical trial?
- What is the current state of outcomes-based agreements for CGT, going beyond CGT Access Model?
- What are the market access (i.e. pricing and coverage) related operational challenges for the hospital when administering CGT, inpatient and outpatient?
- How can the manufacturer assist in resolving these challenges?
- Kris Thiruvillakkat - Senior Director, Global Evidence Market Access & Pricing, CSL Behring
- Important developments in IRA implementation and litigation
- Update on 340B litigation and administrative actions on duplicate discounts and diversion
- Discussion of government efforts to rein in PBM abuses
- James Stansel - Executive Vice President, General Counsel and Corporate Secretary, PhRMA
- Perspective on the OIG's oversight role amidst evolving drug pricing and contracting practices
- Tanaz Dutia - Team Leader and Rapid Response Technical Expert, Office of Inspector General
- Edward Burley - Deputy Regional Inspector General, Office of Inspector General, U.S. Department of Health and Human Services